GE Healthcare Announces $80 Million Investment To Expand Contrast Media Production Capacity
November 17 2022 - 7:35AM
Business Wire
- Capacity expansion at Active Pharmaceutical Ingredient facility
in Lindesnes, Norway, contributes to GE Healthcare’s aim to produce
30 million more doses of contrast media per year by 2025
- This step reinforces GE Healthcare’s broader commitment to
address growing future demand for contrast media, which it expects
to double in the next ten years
GE Healthcare’s Pharmaceutical Diagnostics business announced an
$80 million investment to increase manufacturing capacity by 30
percent at its Active Pharmaceutical Ingredients (API) site in
Lindesnes, Norway. The investment – which is creating around 100
new jobs – is part of GE Healthcare’s broader commitment to address
significant future global demand for iodinated contrast media, used
in Xray and Computed Tomography (CT) procedures around the world to
enhance visualization of organs, blood vessels and tissues across
disease pathways.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20221117005624/en/
GE Healthcare Manufacturing Facility,
Lindesnes, Norway (Photo: Business Wire)
Iohexol and iodixanol API are used in over 100 million patient
doses of GE iodinated contrast media annually, equivalent to three
patient procedures every second. This new investment, coupled with
the recent opening of a new production line at GE Healthcare’s
Cork, Ireland, fill and finish facility, aims to enable the
production of 30 million more patient doses per year by 2025.
President & CEO of GE Healthcare Pharmaceutical Diagnostics,
Kevin O’Neill, said, “We expect global demand for iodinated
contrast media to double in the next 10 years, driven by global
prevalence of chronic disorders and significant growth in CT
procedures. This investment in capacity expansion at our Lindesnes
facility is another example of how we, as an industry leader, are
addressing this growing demand to meet the needs of our customers
and their patients across the globe.”
The 100-acre Lindesnes site in southern Norway, has been
operating since 1974 and employs 450 people, who use multiple
chemical pharmaceutical processes to convert iodine into finished
API. Recently, GE Healthcare announced a multi-year agreement with
SQM, a Chile-based mining company, to secure increasing supply of
iodine, the key ingredient in iodinated contrast media.
GE Healthcare is the world’s leading supplier of contrast media,
used to support patient imaging procedures in 130+ countries
globally. All stages of its contrast media manufacturing, from
development of Active Pharmaceutical Ingredient (API) to finished
product, are managed entirely by GE Healthcare, adhering to current
Good Manufacturing Practices. With over 4000 employees globally and
seven manufacturing sites, the Pharmaceutical Diagnostics business
also develops and supplies radiopharmaceuticals used to support
diagnosis, monitoring and treatment selection across Neurology,
Cardiology and Oncology clinical pathways.
About GE Healthcare: GE Healthcare is the $17.7 billion
healthcare business of GE (NYSE: GE). As a leading global medical
technology, pharmaceutical diagnostics and digital solutions
innovator, GE Healthcare enables clinicians to make faster, more
informed decisions through intelligent devices, data analytics,
applications and services, supported by its Edison intelligence
platform. With over 100 years of healthcare industry experience and
around 48,000 employees globally, the company operates at the
center of an ecosystem working toward precision health, digitizing
healthcare, helping drive productivity and improve outcomes for
patients, providers, health systems and researchers around the
world.
Follow us on Facebook, LinkedIn, Twitter, Instagram and Insights
for the latest news, or visit our website www.gehealthcare.com for
more information.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20221117005624/en/
Media Contact: GE Healthcare
Debbie Leven / Debbie.Leven@ge.com +44 7785 456999
GE Aerospace (NYSE:GE)
Historical Stock Chart
From Mar 2024 to Apr 2024
GE Aerospace (NYSE:GE)
Historical Stock Chart
From Apr 2023 to Apr 2024